O
OraPharma (acquired by JNJ)
And commercializes products that help improve and maintain oral health
About OraPharma (acquired by JNJ)
OraPharma is a specialty pharmaceutical company focused on developing and commercializing therapeutics for the oral health market, specifically targeting dental professionals and their patients. The company was founded in 1996 by Michael Kishbauch.
The company's flagship product is ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) procedures for the treatment of adult periodontitis. This product utilizes a patented microsphere delivery technology to provide a time-released antibiotic directly to the site of infection in the gums. Beyond ARESTIN®, OraPharma's portfolio includes the OSSIX® line of regenerative solutions for oral surgery and the OraFit™ custom clear dental aligner system for correcting malocclusion. The business model centers on selling these specialized products directly to dental professionals, including dentists, hygienists, oral surgeons, and periodontists. The company supports this with a large specialized pharmaceutical sales force and educational initiatives, such as the ARESTIN Student Access Program, which provides training and resources to dental and dental hygiene schools.
OraPharma has a notable corporate history involving multiple acquisitions. In November 2002, Johnson & Johnson announced its agreement to acquire OraPharma for approximately $85 million, a deal that was completed in early 2003. Subsequently, in 2011, the private equity firm Water Street Healthcare Partners acquired OraPharma from Johnson & Johnson with plans to expand its portfolio. This led to another acquisition in June 2012, when Valeant Pharmaceuticals International (now Bausch Health Companies Inc.) purchased OraPharma for approximately $312 million, plus potential milestone payments. Today, OraPharma operates as the oral health care business of Bausch Health, continuing to partner with dental service organizations and professionals nationwide.
Source: Dealroom company dataNews
Open roles
OraPharma (acquired by JNJ) in the Bridgewater ecosystem
The OraPharma (acquired by JNJ) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
HealthCap
Oak Investment
Canaan
TL Ventures
Domain Associates
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OraPharma (acquired by JNJ) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OraPharma (acquired by JNJ) on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


